🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. 0.2 mg/kg ketamine

    United Therapeutics Europe Ltd

    Depression

    phase 3 small molecule terminated

    1 trial

  4. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  5. 0.9% sodium chloride, GB-0895

    Generate Biomedicines

    severe uncontrolled asthma

    phase 3 small molecule active

    1 trial

  6. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  7. 1.0% C31G SAVVY vaginal gel

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule active

    2 trials

  8. 10-week smoking cessation group therapy combined with NicoDerm CQ

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  9. 1:1:1 Blood Transfusion Ratio

    United Therapeutics Europe Ltd

    Trauma

    phase 3 mab completed

    1 trial

  10. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  11. 2 mg Melatonin

    United Therapeutics Europe Ltd

    Anxiety

    phase 3 small molecule completed

    1 trial

  12. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  13. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 3 other active

    1 trial

  14. 4-aminopyridine

    United Therapeutics Europe Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule completed

    1 trial

  15. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 mab active

    1 trial

  16. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Macular Neovascularization Secondary to Age-Related Macular Degeneration

    phase 3 mab active

    1 trial

  17. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule terminated

    3 trials

  18. 5mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule completed

    2 trials

  19. 600 mg Ibuprofen

    United Therapeutics Europe Ltd

    Tibial Fractures

    phase 3 small molecule active

    1 trial

  20. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  21. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Hoffmann-La Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  22. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (BFAST: Blood First Assay Screening Trial)

    Hoffmann-La Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  23. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  24. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources